Linnaeus Therapeutics
Linnaeus Therapeutics is a Healthcare & Life Sciences startup based in the United States, most recent round Series B, 2 tracked investors.
About Linnaeus Therapeutics
Based in the United States, Linnaeus Therapeutics is a startup. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.
Linnaeus Therapeutics is a development-stage biotech company focused on developing small molecule GPER agonists, including their lead candidate LNS8801, for treating multiple diseases such as cancer, cardiometabolic disorders, and aging-related conditions, currently in clinical trials including combination studies with Merck's KEYTRUDA.
Explore Linnaeus Therapeutics's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.